Literature DB >> 12880964

Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?

Debbie Scott1, Joanna Elsden, Andrew Pearson, John Lunec.   

Abstract

Amplification of the MYCN oncogene in neuroblastoma is associated with poor prognosis. The amplified unit of DNA can be up to 1 Mb in size and so could contain additional genes that affect tumour phenotype. Identification of such genes may assist in optimising the determination of prognosis, and could provide new targets for treatment. Three genes have so far been identified, which are frequently co-amplified with MYCN in neuroblastoma, DDX1, NAG and N-cym. In this review, the known or putative properties of the protein products of the genes are discussed, and their possible roles in determining tumour behaviour are assessed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12880964     DOI： 10.1016/s0304-3835(03)00086-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  8 in total

1.  Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.

Authors:  Setsuko Kaneko; Miki Ohira; Yohko Nakamura; Eriko Isogai; Akira Nakagawara; Michio Kaneko
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-07       Impact factor: 4.553

2.  Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure.

Authors:  Clelia Tiziana Storlazzi; Angelo Lonoce; Maria C Guastadisegni; Domenico Trombetta; Pietro D'Addabbo; Giulia Daniele; Alberto L'Abbate; Gemma Macchia; Cecilia Surace; Klaas Kok; Reinhard Ullmann; Stefania Purgato; Orazio Palumbo; Massimo Carella; Peter F Ambros; Mariano Rocchi
Journal:  Genome Res       Date:  2010-07-14       Impact factor: 9.043

3.  Silencing of Nicotiana benthamiana Neuroblastoma-Amplified Gene causes ER stress and cell death.

Authors:  Jae-Yong Lee; Sujon Sarowar; Hee Seung Kim; Hyeran Kim; Inhwan Hwang; Young Jin Kim; Hyun-Sook Pai
Journal:  BMC Plant Biol       Date:  2013-04-27       Impact factor: 4.215

4.  CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma.

Authors:  Haiwei Wang; Xinrui Wang; Liangpu Xu; Yingying Lin; Ji Zhang
Journal:  Dis Markers       Date:  2022-07-28       Impact factor: 3.464

5.  Regulation of MYCN expression in human neuroblastoma cells.

Authors:  Joannes F M Jacobs; Hans van Bokhoven; Frank N van Leeuwen; Christina A Hulsbergen-van de Kaa; I Jolanda M de Vries; Gosse J Adema; Peter M Hoogerbrugge; Arjan P M de Brouwer
Journal:  BMC Cancer       Date:  2009-07-18       Impact factor: 4.430

6.  Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression.

Authors:  R Carter; D Mullassery; V See; S Theocharatos; B Pizer; P D Losty; E Jesudason; D J Moss
Journal:  Oncogenesis       Date:  2012-08-27       Impact factor: 7.485

7.  Episomal amplification of MYCN in a case of medulloblastoma.

Authors:  Cecilia Surace; Florence Pedeutour; Domenico Trombetta; Fanny Burel-Vandenbos; Mariano Rocchi; Clelia Tiziana Storlazzi
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.535

8.  Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons.

Authors:  Katleen De Preter; Filip Pattyn; Geert Berx; Kristin Strumane; Björn Menten; Frans Van Roy; Anne De Paepe; Frank Speleman; Jo Vandesompele
Journal:  BMC Genomics       Date:  2004-02-03       Impact factor: 3.969
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.